Literature DB >> 15793863

Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital.

Yi-Yin Jan1, Chun-Nan Yeh, Ta-Sen Yeh, Tse-Ching Chen.   

Abstract

AIM: To analyze the prognostic factors influencing the overall survival of peripheral cholangiocarcinoma (PCC) patients undergoing surgical treatment during 25 years at a single institution.
METHODS: This study retrospectively reviewed prospectively collecting data about 373 patients with histologically proven PCC who underwent surgical treatment between 1977 and 2001.
RESULTS: Three hundred and seventy-three PCC patients (159 men and 214 women) underwent surgical treatment from 1977 to 2001. Among them, 187 PCC patients underwent hepatectomy and 135 had curative resection (curative resectability rate: 36.2%). The follow-up duration ranged from 1.05 to 167.6 mo (mean/median = 14.1/7.2 mo). Overall cumulative survival rates at 1, 3, and 5 years were 32.5%, 9.2%, and 4.1%, respectively. Univariate log-rank analysis identified the following as adverse influences on overall survival: presence of symptoms, absence of mucobilia, elevated CEA and CA 19-9 levels, non-papillary tumor type, receiving non-hepatectomy, advanced tumor staging, lack of post-operative chemotherapy, and radiotherapy. Meanwhile, multivariate Cox's proportional hazard analysis demonstrated that absence of mucobilia, non-papillary tumor type, advanced tumor staging, non-hepatectomy, and lack of post-operative chemotherapy were the five independent prognostic factors that adversely affected overall survival.
CONCLUSION: Favorable overall survival of PCC patients undergoing surgical treatment depends on early tumor stage, presence of mucobilia, papillary tumor type, hepatic resection, and post-operative chemotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 15793863      PMCID: PMC4305873          DOI: 10.3748/wjg.v11.i12.1779

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan.

Authors:  H Suzuki; S Isaji; C Pairojkul; T Uttaravichien
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

3.  Polypoid epithelial tumors of the bile ducts.

Authors:  R B CATTELL; J W BRAASCH; F KAHN
Journal:  N Engl J Med       Date:  1962-01-11       Impact factor: 91.245

Review 4.  Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment.

Authors:  M F Chen
Journal:  J Gastroenterol Hepatol       Date:  1999-12       Impact factor: 4.029

5.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

6.  A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables.

Authors:  T Okabayashi; J Yamamoto; T Kosuge; K Shimada; S Yamasaki; T Takayama; M Makuuchi
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

Review 7.  Prevention of bile duct cancer in primary sclerosing cholangitis.

Authors:  P M Harrison
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

8.  Clinical studies of mucin-producing cholangiocellular carcinoma: a study of 22 histopathology-proven cases.

Authors:  M F Chen; Y Y Jan; T C Chen
Journal:  Ann Surg       Date:  1998-01       Impact factor: 12.969

9.  Intraductal papillary neoplasia of the liver associated with hepatolithiasis.

Authors:  T C Chen; Y Nakanuma; Y Zen; M F Chen; Y Y Jan; T S Yeh; C T Chiu; T T Kuo; J Kamiya; K Oda; M Hamaguchi; Y Ohno; L L Hsieh; Y Nimura
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

10.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

View more
  19 in total

1.  Outcomes following resection of intrahepatic cholangiocarcinoma.

Authors:  Parissa Tabrizian; Ghalib Jibara; Jaclyn F Hechtman; Bernardo Franssen; Daniel M Labow; Myron E Schwartz; Swan N Thung; Umut Sarpel
Journal:  HPB (Oxford)       Date:  2014-11-14       Impact factor: 3.647

2.  Ruptured peripheral cholangiocarcinoma with hemoperitoneum.

Authors:  Roland W W Chong; Alexander Y F Chung; Ivy W C Chew; Victor K M Lee
Journal:  Dig Dis Sci       Date:  2006-06-14       Impact factor: 3.199

3.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

4.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

5.  Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study.

Authors:  W F Shen; W Zhong; Q Liu; C J Sui; Y Q Huang; J M Yang
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

6.  Diagnosis and surgical treatment of intrahepatic hepatolithiasis combined with cholangiocarcinoma.

Authors:  Qian D Zhu; Meng T Zhou; Qing Q Zhou; Hong Q Shi; Qi Y Zhang; Zheng P Yu
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

7.  Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma.

Authors:  Xiao-Fang Liu; Hao Zhang; Shi-Guang Zhu; Xian-Ting Zhou; Hai-Long Su; Zheng Xu; Shao-Jun Li
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

Review 8.  Liver transplantation for cholangiocarcinoma: Current status and new insights.

Authors:  Gonzalo Sapisochín; Elena Fernández de Sevilla; Juan Echeverri; Ramón Charco
Journal:  World J Hepatol       Date:  2015-10-08

9.  Hepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection.

Authors:  Hua-Bang Zhou; Hui Wang; Yu-Qiong Li; Shuang-Xi Li; Hao Wang; Dong-Xun Zhou; Qian-Qian Tu; Qing Wang; Shan-Shan Zou; Meng-Chao Wu; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

10.  Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Authors:  Johan Fevery; Chris Verslype; Gillian Lai; Raymond Aerts; Werner Van Steenbergen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.